Pragma Bio is a biotechnology startup based in South San Francisco, California, with a mission to find cures for undruggable immunological disorders. With $10 million in funding from investors such as The Venture Collective (TVC) and Viking Global Investors, the company aims to revolutionize how we approach treatments for these disorders.

Using a combination of real-world data and synthetic biology, Pragma Bio can map out multi-omic signatures associated with clinical outcomes, which allows them to identify microbial-derived small molecules with therapeutic potential. By leveraging these small molecules, the company aims to produce effective treatments for immunological disorders that were previously considered incurable.

The potential for this type of approach is immense, as many immunological disorders lack effective treatments due to their complexity and the difficulty of targeting specific cells or biological pathways.

Pragma Bio’s innovative approach has the potential to address these challenges and provide new hope for patients suffering from these conditions. Visit us for more information about their latest funding round: https://founderlodge.com/round/Pragma-Bio-raises-10000000-Unknown-2023-03-27-Kareem-Barghouti-MTE0OTg